Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Ligand Pharmaceuticals (LGND)

Ligand raises low end of 2026 adjusted EPS guidance as Q2 royalty revenue rises 32%

Positive Impact 4 of 5 guidance Written later

Ligand reported second-quarter 2026 total revenue of $63.7 million, up 34% from a year earlier, and GAAP net income of $48.5 million, or $2.22 per diluted share, compared with $4.8 million, or $0.24, in the prior-year quarter. The company raised the low end of its 2026 adjusted EPS guidance to $9.00 to $9.50 and kept its revenue guidance unchanged, which shareholders may weigh against the non-cash gain that boosted GAAP results.

Key points

  • Q2 2026 total revenue was $63.7 million vs. $47.6 million; royalties were $48.0 million vs. $36.4 million.
  • GAAP net income was $48.5 million ($2.22 per diluted share), including a $35.7 million non-cash gain tied to Pelthos Therapeutics investments.
  • Adjusted EPS guidance is now $9.00 to $9.50 (previously $8.50 to $9.50); 2026 total revenue guidance of $270 million to $310 million is reaffirmed.
  • The $700 million 0.00% convertible notes due 2031 closed June 25, 2026; the XOMA Royalty acquisition closed July 14, 2026, with holders receiving $39.00 in cash per share plus a CVR.

The filing

CompanyLigand Pharmaceuticals (LGND)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:05 AM ET
Accession number0000886163-26-000041

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.